22 completed, 2 active not recruiting, 2 not yet recruiting, 2 unknown. 30 Phase 2, 5 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 22, Active not recruiting 2, Not yet recruiting 2, Unknown 2, Withdrawn 2 |
| Phase 1 | 5 | Completed 4, Unknown 1 |
| Phase 3 | 4 | Completed 2, Not yet recruiting 1, Withdrawn 1 |
Follow Filoviridae Infections: new trials by email Literature Review of Filoviridae Infections trials Research Report on Filoviridae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers Ervebo, Inmazeb - Ebola Virus Disease | Phase 2 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 132 | 2027-01-01 | 2026-01-22 |
| Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo Candidate BDBV vaccine, Active comparator - Ebola Hemorrhagic Fever, Bundibugyo Virus Disease | Phase 2 / Phase 3 | Not yet recruiting | Jean-Pierre Van geertruyden | 3620 | 2026-10-20 | 2026-10-05 |
| A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults cAd3-Marburg Vaccine, Placebo - Marburg Virus Disease | Phase 2 | Active not recruiting | Albert B. Sabin Vaccine Institute | 200 | 2025-04-14 | 2026-09-10 |
| Immunology of Ebola Vaccine Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water - Ebola Virus Disease | Phase 2 | Active not recruiting | Emory University | 30 | 2024-08-06 | 2026-01-22 |
| Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults cAd3-Marburg vaccine, Placebo - Marburg Virus Disease | Phase 2 | Completed | Albert B. Sabin Vaccine Institute | 126 | 2023-10-19 | 2025-07-23 |
| Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study Ad26.ZEBOV, MVA-BN-Filo - Virus Diseases, Hemorrhagic Fever, Ebola | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 133 | 2022-09-19 | 2025-05-11 |
| Prophylaxis Vaccine Antibodies Ebola ansuvimab, Ervebo - Ebola Virus Disease | Phase 2 | Unknown | ANRS, Emerging Infectious Diseases | 250 | 2021-10-17 | 2021-10-15 |
| Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study) Ad26.ZEBOV - Ebola Virus Disease, Ebola | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 26 | 2021-10-06 | 2023-02-21 |
| Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study) Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection - Ebola Virus Disease | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 50 | 2021-07-08 | 2023-12-13 |
| Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy Remdesivir - Ebola, HIV/AIDS | Phase 2 | Completed | Makerere University | 24 | 2021-05-05 | 2021-08-25 |
| Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon rVSVΔG-ZEBOV-GP, V920, Fibre and equilibrate breakfast and lunch, Active detection and treatment of pathogens - Ebola Virus Disease | Phase 1 / Phase 2 | Completed | Centre de Recherche Médicale de Lambaréné | 120 | 2021-04-09 | 2023-04-20 |
| Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola Ad26.ZEBOV vaccine - Ebola Virus Disease | Phase 2 | Completed | Universiteit Antwerpen | 699 | 2019-12-18 | 2026-07-14 |
| A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants Ad26.ZEBOV, MVA-BN-Filo, MenACWY - Ebola Virus Disease | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 108 | 2019-08-19 | 2025-05-25 |
| ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo) Ad26.ZEBOV/MVA-BN-Filo - Ebola Virus Disease | Phase 2 | Completed | MRC/UVRI and LSHTM Uganda Research Unit | 800 | 2019-08-01 | 2021-05-12 |
| A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-Lyo GamEvac-Lyo (component A), Placebo, GamEvac-Lyo (component B) - Healthy Volunteers | Phase 1 / Phase 2 | Completed | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 220 | 2017-11-03 | 2019-11-14 |
| African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine, Saline - Ebola | Phase 2 | Completed | Canadian Immunization Research Network | 251 | 2017-08-01 | 2026-01-12 |
| Partnership for Research on Ebola VACcinations Ad26.ZEBOV, MVA-BN-Filo, rVSVΔG-ZEBOV-GP - Ebola Virus Disease | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 4789 | 2017-03-27 | 2024-06-26 |
| GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen GS-5734, Placebo Comparator - Ebola | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 38 | 2016-07-01 | 2022-02-15 |
| Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo Ad26.ZEBOV, MVA-BN-Filo, Placebo - Hemorrhagic Fever, Ebola | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 578 | 2015-12-10 | 2025-02-04 |
| Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults Ad26.ZEBOV, MVA-BN-Filo, Placebo - Hemorrhagic Fever, Ebola | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 1075 | 2015-11-06 | 2022-03-07 |
Showing 20 of 30. Sign in to see all of them.
Hemorrhagic Fever, Ebola (28) · Hemorrhagic Fevers, Viral (5) · Acquired Immunodeficiency Syndrome (2) · Marburg Virus Disease (2) · RNA Virus Infections (2) · Infections (1) · Mononegavirales Infections (1) · Virus Diseases (1)
Infections (29) · Mononegavirales Infections (29) · Virus Diseases (29) · RNA Virus Infections (28) · Hemorrhagic Fevers, Viral (25) · Animal Diseases (2) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · HIV Infections (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Lentivirus Infections (2) · Monkey Diseases (2)
Ebola Vaccines (2) · favipiravir (2) · remdesivir (2) · Amiodarone (1) · Atorvastatin (1) · Azithromycin (1) · Chickenpox Vaccine (1) · Deuterium Oxide (1) · Dietary Fiber (1) · Erlotinib Hydrochloride (1) · Fluid Therapy (1) · Irbesartan (1) · Lunch (1) · MenACWY (1) · Sodium Chloride (1)
Janssen Vaccines & Prevention B.V. (3) · London School of Hygiene and Tropical Medicine (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · ANRS, Emerging Infectious Diseases (2) · Albert B. Sabin Vaccine Institute (2) · Beijing Institute of Pharmacology and Toxicology (1) · Canadian Immunization Research Network (1) · Centers for Disease Control and Prevention (1) · Centre Hospitalier Universitaire Vaudois (1) · Centre de Recherche Médicale de Lambaréné (1) · Clinical Research Management, Inc. (1) · Emergency NGO Onlus (1) · Emory University (1) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (1) · Institut National de la Santé Et de la Recherche Médicale, France (1)
Guinea (7) · Sierra Leone (7) · Uganda (6) · Kenya (4) · United States (4) · Liberia (3) · Democratic Republic of the Congo (2) · Burkina Faso (1) · Canada (1) · Côte d’Ivoire (1) · Gabon (1) · Mali (1) · Mozambique (1) · Nigeria (1) · Russia (1)
Deborah Watson-Jones, PhD (2) · Abdoul Habib Beavogui (1) · Ali Ellebedy, PhD (1) · Alie H Wurie (1) · Bailah Leigh (1) · Bailah Leigh, MD (1) · Blaise Genton, MD PhD (1) · Cecile Tremblay, MD (1) · Christopher Woods, MD, MPH (1) · David L Hoover, MD (1) · Deborah L Watson-Jones, PhD (1) · Denis Malvy, Professor (1) · Elizabeth S Higgs, M.D. (1) · Hypolite Mavoko Muhindo, Dr. (1)
PMID 11395204, PMID 14741143, PMID 17548132, PMID 17553602, PMID 22342706, PMID 23125444, PMID 23170176, PMID 24738640, PMID 26725450, PMID 26735992, PMID 26768569, PMID 26768570, PMID 26930627, PMID 27046271, PMID 27732819, PMID 27959686, PMID 28231247, PMID 28647166, PMID 29788339, PMID 29788340, PMID 29788341, PMID 29788342, PMID 29788343, PMID 29788345, PMID 29788346, PMID 29788347, PMID 29788348, PMID 29788349, PMID 30239838, PMID 32017677, PMID 33485369, PMID 33709142, PMID 34378545, PMID 34588237, PMID 34714820, PMID 34814933, PMID 35015777, PMID 35127447, PMID 35550847, PMID 36208978, PMID 36273490, PMID 36516078, PMID 37858585, PMID 37967326, PMID 37981473, PMID 37993355, PMID 38552653, PMID 38603720, PMID 38657084, PMID 38793748
2019 (1)